Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.
All News
Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.
On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD. In early developmental trials this agent was also called SB2.
Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.
Dr. Jack Cush reviews highlights from the news and Advances in Targeted Therapies meeting in Mandelieu, France:
Tweeting this week from Advances in Targeted Therapies #ATT2017 in Mandelieu, France.
Tumor necrosis factor-α inhibitors (TNFi) rarely have been reported to induce new-onset psoriasis.
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Dr. Jack Cush reviews highlights in the news from the past week at RheumNow.com. News on hepatitis C in RA and risk of hepatotoxicity; TNF inhibitor persistence in PsA; unnecessary injections in pre-operative OA knee patients; and a delay in the FDA decision on abaloparatide.
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
A recent study reports that obesity is linked to late-onset psoriasis and psoriatic arthritis (PsA). By contrast being of normal weight may be associated with an earlier onset of the disease adn HLA-B27.
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
Treatment of systemic sclerosis is difficult, as there have few proven therapies capable of altering the course of the disease. Ideally, early intervention affords the optimal scenario wherein drug intervention can be proven to work.
New research confirms that patients with psoriatic arthritis (PsA) face significant healthcare and socioeconomic hurdles.
Doubt remains regarding the appropriateness, efficacy and safety of methotrexate in the treatment of moderate to severe cutaneous psoriasis. Moreover, high dose, subcutaneous MTX has not been studied in a well-designed trial.
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.
Dr. Cush reviews highlights from the past week on RheumNow.com.
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
